Role of prostacyclin in pulmonary hypertension

Global Cardiology Science and Practice

Volumn 2014, Issue 4, 2014, Pages

  Mitchell, Jane A ^a   Ahmetaj Shala, Bierina ^a   Kirkby, Nicholas S ^a   Wright, William R ^a   Mackenzie, Louise S ^a   Reed, Daniel M ^a   Mohamed, Nura ^a  

^a NHLI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ILOPROST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROSTACYCLIN; SELEXIPAG; THROMBOXANE RECEPTOR; TREPROSTINIL; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID;

ARTICLE; CATHETER INFECTION; CLINICAL FEATURE; CONTINUOUS INFUSION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; EXERCISE TEST; HOT FLUSH; HUMAN; HYPOTENSION; JAW PAIN; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEPSIS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TISSUE REGENERATION;

EID: 85045963744     PISSN: None     EISSN: 23057823     Source Type: Journal    
DOI: 10.5339/gcsp.2014.53     Document Type: Article

References (73)

1. Moncada S, Gryglewski R, Bunting S., Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976; 263:663-665
2. Bunting S, Gryglewski R, Moncada S., Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin x) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins. 1976; 12:897-913
3. Whittaker N, Bunting S, Salmon J., Moncada S, Vane JR, Johnson R.A., Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF. The chemical structure of prostaglandin x (prostacyclin). Prostaglandins. 1976; 12:915-928
4. Moncada S, Herman AG, Higgs E.A., Vane JR. Differential formation of prostacyclin (pgx or pgi2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res. 1977; 11:323-344
5. Smith WL The eicosanoids and their biochemical mechanisms of action. Biochem J. 1989; 259:315-324
6. Christman BW, McPherson CD, Newman J.H., King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327:70-75
7. Tuder RM, Cool CD, Geraci M.W., Wang J., Abman SH, Wright L, Badesch D, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999; 159:1925-1932
8. Gubrij IB, Martin SR, Pangle A.K., Kurten R., Johnson LG. Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Hum Gene Ther. 2014; 25:498-505
9. Nagaya N, Yokoyama C, Kyotani S., Shimonishi M, Morishita R, Uematsu M., Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, Miyatake K, Kaneda Y, Tanabe T. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation. 2000; 102:2005-2010
10. Geraci MW, Gao B, Shepherd D.C., Moore MD, Westcott JY, Fagan KA, Alger L.A., Tuder RM, Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999; 103:1509-1515
11. Zhou L, Chen Z, Vanderslice P., So SP, Ruan KH, Willerson JT, Dixon RA. Endothelial-like progenitor cells engineered to produce prostacyclin rescue monocrotaline-induced pulmonary arterial hypertension and provide right ventricle benefits. Circulation. 2013; 128:982-994
12. Takemiya K, Kai H, Yasukawa H., Tahara N, Kato S, Imaizumi T. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol. 2010; 105:409-417
13. Giacomini KM, Huang SM, Tweedie D.J., Benet LZ, Brouwer KL, Chu X, Dahlin A., Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9:215-236
14. Warner TD, Mitchell JA. Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy as abc? Proc Natl Acad Sci USA. 2003; 100:9108-9110
15. Hara Y, Sassi Y, Guibert C., Gambaryan N, Dorfmuller P, Eddahibi S., Lompre AM, Humbert M, Hulot JS. Inhibition of mrp4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011; 121:2888-2897
16. Hewer RC, Sala-Newby GB, Wu Y.J., Newby AC, Bond M. Pka and epac synergistically inhibit smooth muscle cell proliferation. Journal of molecular and cellular cardiology. 2011; 50:87-98
17. F Murray RS, O Kwon, X Li, CV Remillard, PA Thistlethwaite, JX Yuan, PA Insel, http://www.atsiournals.org/doi/abs/10.1164/ajrccm-conference.2009.179.1MeetingAbstracts. A1804 RM. Decreased expression and activity of epac (exchange protein directly activated by camp) in pulmonary arterial hypertension
18. Wilson SM, Sheddan NA, Newton R, Giembycz MA. Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of cxcl9 and cxcllO release. Molecular pharmacology. 2011; 79:586-595
19. Giguere V, Gallant MA, de Brum-Fernandes AJ, Parent JL Role of extracellular cysteine residues in dimerization/oligomerization of the human prostacyclin receptor. European journal of pharmacology. 2004; 494:11-22
20. Wilson SJ, Roche AM, Kostetskaia E, Smyth EM. Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated camp generation. The Journal of biological chemistry. 2004; 279:53036-53047
21. Smyth EM, Li WH, FitzGerald GA. Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinasec. The Journal of biological chemistry. 1998; 273:23258-23266
22. Smyth EM, Austin SC, Reilly M.P., FitzGerald GA. Internalization and sequestration of the human prostacyclin receptor. The Journal of biological chemistry. 2000; 275:32037-32045
23. Barst RJ, Rubin U, Long W.A., McGoon MD, Rich S, Badesch DB, Groves B.M., Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW, Primary Pulmonary Hypertension Study G. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334:296-301
24. McLaughlin VV, Genthner DE, Panella M.M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998; 338:273-277
25. Archer SL, Mike D, Crow J., Long W, Weir EK. A placebo-controlled trial of prostacyclin in acute respiratory failure in copd. Chest. 1996; 109:750-755
26. Belvisi MG, Mitchell JA. Targeting ppar receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol. 2009; 158:994-1003
27. AN FY, Davidson SJ, Moraes L.A., Traves SL, Paul-Clark M, Bishop-Bailey D, Warner T.D., Mitchell JA. Role of nuclear receptor signaling in platelets: Antithrombotic effects of pparbeta. Faseb J. 2006; 20:326-328
28. AN FY, Egan K, FitzGerald G.A., Desvergne B., Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol. 2006; 34:242-246
29. Harrington LS, Moreno L, Reed A., Wort SJ, Desvergne B, Garland C, Zhao L., Mitchell JA. The pparbeta/delta agonist gw0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One. 2010; 5:e9526
30. Li Y, Connolly M, Nagaraj C., Tang B, Balint Z, Popper H., Smolle-Juettner FM, Lindenmann J, Kwapiszewska G, Aaronson PI, Wohlkoenig C, Leithner K, Olschewski H, Olschewski A. Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation. Am J Respir Cell Mol Biol. 2012; 46:372-379
31. Kojonazarov B, Luitel H, Sydykov A., Dahal BK, Paul-Clark MJ, Bonvini S, Reed A., Schermuly RT, Mitchell JA. The peroxisome proliferator-activated receptor beta/delta agonist gw0742 has direct protective effects on right heart hypertrophy. Pulm Circ. 2013; 3:926-935
32. Liu J, Wang P, Luo J., Huang Y, He L, Yang H., Li Q, Wu S, Zhelyabovska O, Yang Q. Peroxisome proliferator-activated receptor beta/delta activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition. Hypertension. 2011; 57:223-230
33. Simonson TS, Yang Y, Huff C.D., Yun H., Qin G, Witherspoon DJ, Bai Z, Lorenzo F.R., Xing J., Jorde LB, Prchal JT, Ge R. Genetic evidence for high-altitude adaptation in tibet. Science. 2010; 329:72-75
34. Galaup A, Gomez E, Souktani R., Durand M, Cazes A, Monnot C., Teillon J, Le Jan S, Bouleti C, Briois G, Philippe J, Pons S, Martin V, Assaly R, Bonnin P, Ratajczak P, Janin A, Thurston G, Valenzuela DM, Murphy AJ, Yancopoulos GD, Tissier R, Berdeaux A, Ghaleh B, Germain S. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation. 2012; 125:140-149
35. Sprecher DL, Massien C, Pearce G., Billin AN, Perlstein I, Willson TM, Hassall D.G., Ancellin N., Patterson SD, Lobe DC, Johnson TG. Triglyceride: High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol. 2007; 27:359-365
36. L. E. Geiger WSD, D. J. Lewis, C. Brennan, K. C. Liu and S. J. Newsholme. 895-rat carcinogenicity study with gw501516, appar delta agonist. Society of Toxicology. 2009
37. S. J. Newsholme WSD, T. Brodie, C. Brennan, M. Brown and L. E. Geiger 896 - mouse carcinogenicity study with gw501516, a ppar delta agonist. Society of Toxicology. 2009
38. Mitchell JA, Warner TD. Cox isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006; 5:75-86
39. Kirkby NS, Lundberg MH, Harrington L.S., Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O., Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA. 2012; 109:17597-17602
40. Kirkby NS, Zaiss AK, Urquhart P, Jiao J., Austin PJ, Al-Yamani M, Lundberg MH, MacKenzie L.S., Warner TD, Nicolaou A, Herschman HR, Mitchell JA. Lc-ms/ms confirms that cox-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of cox-2 expression. PLoS One. 2013; 8:e69524
41. Liu B, Luo W, Zhang Y., Li H, Zhu N, Huang D., Zhou Y. Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ach in mouse arteries. Exp Physiol. 2012; 97:277-289
42. Kirkby NS, Lundberg MH, Wright W.R., Warner TD, Paul-Clark MJ, Mitchell JA. Cox-2 protects against atherosclerosis independently of local vascular prostacyclin: Identification of cox-2 associated pathways implicate rgl1 and lymphocyte networks. PLoS One. 2014; 9:e98165
43. Kirkby NS, Chan MV, Lundberg M.H., Massey KA, Edmands WM, MacKenzie LS, Holmes E, Nicolaou A., Warner TD, Mitchell JA. Aspirin-triggered 15-epi-lipoxin a4 predicts cyclooxygenase-2 in the lungs of Ips-treated mice but not in the circulation: Implications for a clinical test. Faseb J. 2013; 27:3938-3946
44. Pugliese SC, Poth JM, Fini M.A., Olschewski A., El Kasmi KC, Stenmark KR. The role of inflammation in hypoxic pulmonary hypertension: From cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol. 2014:ajplung 00238 02014.
45. Rabinovitch M, Guignabert C, Humbert M., Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014; 115:165-175
46. Cracowski JL, Chabot F, Labarere J., Faure P, Degano B, Schwebel C., Chaouat A, Reynaud-Gaubert M, Cracowski C, Sitbon O, Yaici A, Simonneau G, Humbert M. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J. 2014; 43:915-917
47. Soon E, Holmes AM, Treacy C.M., Doughty NJ, Southgate L, Machado RD, Trembath R.C., Jennings S., Barker L, Nicklin P, Walker C, Budd DC, Pepke-Zaba J, Morrell NW. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010; 122:920-927
48. George PM, Oliver E, Dorfmuller P., Dubois OD, Reed DM, Kirkby NS, Mohamed N.A., Perros F., Antigny F, Fadel E, Schreiber BE, Holmes AM, Southwood M, Hagan G, Wort SJ, Bartlett N, Morrell NW, Coghlan JG, Humbert M, Zhao L, Mitchell JA. Evidence for the involvement of type i interferon in pulmonary arterial hypertension. Circ Res. 2014; 114:677-688
49. George PM, Badiger R, Alazawi W., Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012; 135:44-53
50. Jourdan KB, Evans TW, Lamb N.J., Goldstraw P., Mitchell JA. Autocrine function of inducible nitric oxide synthase and cyclooxygenase-2 in proliferation of human and rat pulmonary artery smooth-muscle cells: Species variation. Am J Respir Cell Mol Biol. 1999; 21:105-110
51. Bradbury DA, Newton R, Zhu Y.M., Stocks J., Corbett L, Holland ED, Pang L.H., Knox AJ. Effect of bradykinin, tgf-betal, il-1beta, and hypoxia on cox-2 expression in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2002; 283:L717-725
52. Yang X, Sheares KK, Davie N, Upton P.D., Taylor GW, Horsley J, Wharton J, Morrell NW. Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2002; 27:688-696
53. Sheares KK, Jeffery TK, Long L, Yang X., Morrell NW. Differential effects of tgf-betal and bmp-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2004; 287:L919-927
54. Cathcart MC, Tamosiuniene R, Chen G., Neilan TG, Bradford A, O'Byrne KJ, Fitzgerald DJ, Pidgeon GP. Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther. 2008; 326:51-58
55. Fredenburgh LE, Liang OD, Macias A.A., Polte TR, Liu X, Riascos DF, Chung S.W., Schissel SL, Ingber DE, Mitsialis SA, Kourembanas S, Perrella MA. Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation. 2008; 117:2114-2122
56. Rakotoniaina Z, Guerard P, Lirussi F., Rochette L, Dumas M, Goirand F., Bardou M. Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. Naunyn Schmiedebergs Arch Pharmacol. 2008; 378:241-251
57. Hossmann V, Auel H, Rucker W., Schror K. Prolonged infusion of prostacyclin in patients with advanced stages of peripheral vascular disease: A placebo-controlled cross-over study. Klinische Wochenschrift. 1984; 62:1108-1114
58. Taichman DB, Ornelas J, Chung L., Klinger JR, Lewis S, Mandel J, Palevsky H.I., Rich S., Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic therapy for pulmonary arterial hypertension in adults: Chest guideline and expert panel report. Chest. 2014; 146:449-475
59. Butrous G. The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Global Cardiology Science and Practice. 2014; 42:10.5339/gcsp.2014.5342
60. Nguyen H, Amanullah AM. Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease. Reviews in cardiovascular medicine. 2014; 15:158-167
61. Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Global cardiology science & practice. 2014; 2014:62-78
62. Kirkby NS, Lundberg MH, Chan M.V., Vojnovic I., Solomon AB, Emerson M, Mitchell JA, Warner TD. Blockade of the purinergic p2yl2 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A. 2013; 110:15782-15787
63. George PM, Oliver E, Dorfmuller P., Dubois OD, Reed DM, Kirkby NS, Mohamed N.A., Perros F., Antigny F, Fadel E, Schreiber BE, Holmes AM, Southwood M, Hagan G, Wort SJ, Bartlett N, Morrell NW, Coghlan JG, Humbert M, Zhao L, Mitchell JA. Evidence for the involvement of type i interferon in pulmonary arterial hypertension. Circ Res. 2014; 114:677-688
64. Lavoie JR, Ormiston ML, Perez-lratxeta C, Courtman D.W., Jiang B., Ferrer E, Caruso P, Southwood M., Foster WS, Morrell NW, Stewart DJ. Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation. 2014; 129:2125-2135
65. Simonneau G, Torbicki A, Hoeper M.M., Delcroix M., Karlocai K, Galie N, Degano B., Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM. Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012; 40:874-880
66. http://clinicaltrials.gov/ct2/show/NCT01106014.
67. http://wwwl.actelion.com/en/scientists/development-pipeline/phase-3/selexipag.page.
68. Feldman J, Im Y, Gill K. Oral treprostinil diethanolamine for pulmonary arterial hypertension. Expert review of clinical pharmacology. 2015; 8:55-60
69. Tapson VF, Jing ZC, Xu K.F., Pan L., Feldman J, Kiely DG, Kotlyar E, McSwain C.S., Laliberte K., Arneson C, Rubin U, Team F-CS. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the freedom-c2 study): A randomized controlled trial. Chest. 2013; 144:952-958
70. Tapson VF, Torres F, Kermeen F., Keogh AM, Allen RP, Frantz RP, Badesch D.B., Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galie N. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the freedom-c study): A randomized controlled trial. Chest. 2012; 142:1383-1390
71. Ryan SM, Brayden DJ. Progress in the delivery of nanoparticle constructs: Towards clinical translation. Current opinion in pharmacology. 2014; 18C:120-128
72. Mosgoeller W, Prassl R, Zimmer A. Nanoparticle-mediated treatment of pulmonary arterial hypertension. Methods in enzymology. 2012; 508:325-354
73. Ruan CH, Dixon RA, Willerson J.T., Ruan KH. Prostacyclin therapy for pulmonary arterial hypertension. Texas Heart Institute journal /from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital. 2010; 37:391-399